David K Clarke
Overview
Explore the profile of David K Clarke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilson G, Rodriguez B, Li S, Allen M, Frank I, Rudnicki E, et al.
Vaccine
. 2023 Mar;
41(16):2696-2706.
PMID: 36935288
Background: HIV subtypes B and C together account for around 60% of HIV-1 cases worldwide. We evaluated the safety and immunogenicity of a subtype B DNA vaccine prime followed by...
2.
Clarke D, Xu R, Matassov D, Latham T, Ota-Setlik A, Gerardi C, et al.
Lancet Infect Dis
. 2020 Jan;
20(4):455-466.
PMID: 31952923
Background: The safety and immunogenicity of a highly attenuated recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1) was shown in previous phase 1 clinical studies. An rVSV vector expressing...
3.
P Monath T, Fast P, Modjarrad K, Clarke D, Martin B, Fusco J, et al.
Vaccine X
. 2019 Aug;
1:100009.
PMID: 31384731
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety and characteristics of live, recombinant viral vector vaccines. A recent publication by the V3SWG...
4.
Elizaga M, Li S, Kochar N, Wilson G, Allen M, Tieu H, et al.
PLoS One
. 2018 Sep;
13(9):e0202753.
PMID: 30235286
Background: The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. The objective of this study...
5.
Suksanpaisan L, Xu R, Tesfay M, Bomidi C, Hamm S, Vandergaast R, et al.
Mol Ther Oncolytics
. 2018 Jul;
10:1-13.
PMID: 29998190
Immunotherapy for HPV malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including...
6.
Matassov D, Mire C, Latham T, Geisbert J, Xu R, Ota-Setlik A, et al.
J Virol
. 2017 Nov;
92(3).
PMID: 29142131
Previous studies demonstrated that a single intramuscular (i.m.) dose of an attenuated recombinant vesicular stomatitis virus (rVSV) vector (VesiculoVax vector platform; rVSV-N4CT1) expressing the glycoprotein (GP) from the Mayinga strain...
7.
Li S, Kochar N, Elizaga M, Hay C, Wilson G, Cohen K, et al.
Clin Vaccine Immunol
. 2017 Sep;
24(11).
PMID: 28931520
The HIV Vaccine Trials Network (HVTN) 087 vaccine trial assessed the effect of increasing doses of pIL-12 (interleukin-12 delivered as plasmid DNA) adjuvant on the immunogenicity of an HIV-1 multiantigen...
8.
Nasar F, Matassov D, Seymour R, Latham T, Gorchakov R, Nowak R, et al.
J Virol
. 2017 Feb;
91(8).
PMID: 28148802
The demonstrated clinical efficacy of a recombinant vesicular stomatitis virus (rVSV) vaccine vector has stimulated the investigation of additional serologically distinct vectors as therapeutic and/or prophylactic vaccine vectors to combat...
9.
Clarke D, Hendry R, Singh V, Rose J, Seligman S, Klug B, et al.
Vaccine
. 2016 Jul;
34(51):6597-6609.
PMID: 27395563
The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous viral and other microbial pathogens...
10.
Fuchs J, Frank I, Elizaga M, Allen M, Frahm N, Kochar N, et al.
Open Forum Infect Dis
. 2015 Jul;
2(3):ofv082.
PMID: 26199949
Background. We report the first-in-human safety and immunogenicity evaluation of a highly attenuated, replication-competent recombinant vesicular stomatitis virus (rVSV) human immunodeficiency virus (HIV)-1 vaccine. Methods. Sixty healthy, HIV-1-uninfected adults were...